Sputnik V vaccine approved in Moldova

CHISINAU, March 3 – RIA Novosti. The National Advisory Committee of Experts in the Field of Immunization of the Ministry of Health of Moldova decided to use 10 types of vaccines against coronavirus, including the Russian vaccine Sputnik V, the press service of the Ministry of Health said.

“In the context of the epidemiological situation, today, on March 3, a meeting of the National Advisory Committee of Experts in the Field of Immunization was held, during which the vaccination process was discussed. The members of the committee approved the use of vaccines in Moldova, which received authorizations in the countries of origin and were included in the WHO lists,” said in a message published on the website of the Ministry of Health.

Thus, the approved use of the following types of vaccines: Pfizer Biontech, AstraZeneca – UK, AstraZeneca – Sk Bio, AstraZeneca – SII, Sinopharm, Sinovac, Moderna, Janssen, The Gamaleya National Center (“Sputnik” V), CanSinoBio. It is noted that the list can be expanded.

Romanian President Klaus Iohannis, during an official visit to Chisinau at the end of last year, promised to provide Moldova with 200 thousand doses of coronavirus vaccine as humanitarian aid, the first batch of 21.6 thousand doses of AstraZeneca vaccine arrived in Chisinau on February 27. Moldova also plans to receive a vaccine from Lithuania free of charge. In addition, in the coming days, the country will receive the first batch of AstraZeneca coronavirus vaccine in a volume of 14.4 thousand doses through the COVAX platform. On February 26, the Moldovan Medicines Agency registered three coronavirus vaccines – Pfizer, AstraZeneca and Sputnik V.

The Sputnik V vaccine was registered by the Ministry of Health of the Russian Federation in August 2020, it was developed by the Gamaleya Research Center for Electrochemistry. This vaccine was the first in the world to prevent COVID-19. Sputnik V is built on a well-studied and proven platform of human adenoviral vectors. The scientific journal Lancet has previously published the results of the third phase of clinical trials “Sputnik V”, confirming its high efficiency and safety.

During phase III clinical trials, Sputnik V demonstrated high rates of efficacy, immunogenicity and safety – the vaccine efficacy was 91.6%. The vaccine provides complete protection against severe cases of the new coronavirus infection. Sputnik V has been approved for use in more than 30 countries.

Read all Moldovan news on the Sputnik Moldova website >>

Author: wedocount

Leave a Reply

Your email address will not be published. Required fields are marked *